GPC1 and pancreatic neoplasm: The PDACEV signature calculated as the unweighted sum of EGFR, EPCAM, MUC1, GPC1, and WNT2 signals showed an 86% sensitivity and 81% specificity in distinguishing pancreatic cancer patients from healthy controls.